Stay updated on Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.

Latest updates to the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page has updated its date references, removing older dates and adding new ones, while the address for Hirakata, Japan has been slightly modified in formatting. The changes reflect a shift in time-sensitive information.SummaryDifference0.2%
- Check13 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check20 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding a Phase 3 clinical trial for amivantamab and the addition of identifiers related to advanced or metastatic non-small cell lung cancer.SummaryDifference11%
- Check28 days agoChange DetectedThe page has removed the phrase 'Last Update Posted (Estimated)' and replaced it with 'Last Update Posted'.SummaryDifference0.0%
- Check35 days agoChange DetectedThe page has been updated to reflect a new version (v2.14.4) and includes new dates for updates, while previous dates and the last update version have been removed.SummaryDifference0.2%
- Check42 days agoChange DetectedThe page has been updated to reflect a new version (v2.14.3) and a new last update date of March 25, 2025, replacing the previous version (v2.14.2) and date of March 4, 2025.SummaryDifference0.1%
Stay in the know with updates to Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.